Purdue Pharma settlement talks to resolve opioid cases focus on a bankruptcy deal valued at up to $12 billion in which the Sacklers cede ownership
OxyContin maker Purdue Pharma LP and its owners, the Sackler family, are in talks with state and local governments to resolve more than 2,000 opioid cases in a deal valued at between $10 billion and $12 billion, according to people familiar with the matter.
The discussions, part of a mediation to end the mounting litigation that seeks to blame Purdue for fueling the opioid crisis, have been ongoing for more than a year and are still in flux, the people said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Purdue Pharma offers $10-12 billion to settle opioid claimsPurdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10B to $12B, according to 2 people familiar with the mediation.
Read more »
Purdue Pharma offers $10-12B to settle 2,000+ opioid lawsuitsPurdue Pharma and its owners, the Sackler family, are offering to settle more than 2,000 lawsuits against the company for $10B to $12B, according to 2 people familiar with the mediation.
Read more »
Report: Purdue Pharma Offered $10-12 Billion To Settle Thousands Of Opioid LawsuitsThe Sackler family is facing increasing blame for fueling the opioid crisis.
Read more »
Purdue Pharma Offers Massive Settlement for Role in Opioid CrisisThe Sackler family will reportedly give up their ownership of the company as part of the $10-12 billion settlement.
Read more »
Purdue Pharma in discussion on $10 billion-$12 billion offer to settle opioid claims: sourcesOxyContin maker Purdue Pharma and its owners, the Sackler family, is in discussi...
Read more »
Purdue Pharmaceuticals Offers to Settle Thousands of Lawsuits for $10-$12 BillionReport comes one day after a judge ordered Johnson & Johnson to pay $572 million to the state of Oklahoma for its role in the opioid crisis
Read more »